BRENDA home
History
Information on EC 2.3.2.5 - glutaminyl-peptide cyclotransferase
for references in articles please use BRENDA:EC2.3.2.5Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.3.2.5 glutaminyl-peptide cyclotransferaseIUBMB Comments
Involved in the formation of thyrotropin-releasing hormone and other biologically active peptides containing N-terminal pyroglutamyl residues. The enzyme from papaya also acts on glutaminyl-tRNA.
Specify your search results
Word Map
- 2.3.2.5
- pyroglutamate
- alzheimer
- cyclases
-
pyroglutamyl
- papaya
-
pglu-a
-
pyroglutamate-modified
-
antivenomics
- medicine
- drug development
- pharmacology
-
cd47-sirp
-
n-truncated
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
Synonyms
AtQC, cyclotransferase, glutaminyl-transfer ribonucleate, DromeQC, gamma-glutamylamine cyclotransferase, GGACT, glutamine cyclotransferase, glutaminyl cyclase, glutaminyl-peptide cyclotransferase-like protein, glutaminyl-tRNA cyclotransferase, golgi resident enzyme, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
cyclotransferase, glutaminyl-transfer ribonucleate
-
-
-
-
DromeQC
glutaminyl cyclase
glutaminyl-tRNA cyclotransferase
-
-
-
-
h-isoQC
hQC
isoDromeQC
isoQC
QC
Qpct
sQC
glutaminyl cyclase
-
-
-
-
glutaminyl cyclase
-
-
glutaminyl cyclase
-
QC
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
L-glutaminyl-peptide = 5-oxoprolyl-peptide + NH3
-
-
-
-
L-glutaminyl-peptide = 5-oxoprolyl-peptide + NH3
general acid/base working mechanism, pivoting around a strictly conserved glutamate
L-glutaminyl-peptide = 5-oxoprolyl-peptide + NH3
DFT theoretical investigation on the catalytic mechanism of glutaminyl cyclase
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
aminoacyl group transfer
aminoacyl group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
MetaCyc
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
L-glutaminyl-peptide gamma-glutamyltransferase (cyclizing)
Involved in the formation of thyrotropin-releasing hormone and other biologically active peptides containing N-terminal pyroglutamyl residues. The enzyme from papaya also acts on glutaminyl-tRNA.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
37257-21-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
amyloid peptide Abeta(3-40/42)
pGluAbeta(3-40/42) + H2O
-
-
significant portion of Abeta peptides of amyloid plaques in Alzheimer's disease brains
-
?
Gln-7-amido-4-methylcoumarin
L-pyroglutamyl-4-methylcoumarin-7-amide + NH3
-
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
pyroglutamate-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
L-Gln-L-Asn-Gly-L-Ile-NH2
L-pyroglutamyl-L-Asn-Gly-L-Ile-NH2 + NH3
-
-
-
?
L-Gln-L-Glu-L-Tyr-L-Ala-NH2
pyroglutamic acid-L-Glu-L-Tyr-L-Ala-NH2 + NH3
-
-
-
?
L-Gln-L-Lys-L-Arg-L-Leu
5-oxoprolyl-L-Lys-L-Arg-L-Leu + NH3
-
-
-
?
L-Gln-L-Phe-L-Ala
5-oxoprolyl-L-Phe-L-Ala + NH3
-
-
-
?
L-Gln-L-Ser-L-Tyr-L-Phe-NH2
pyroglutamic acid-L-Ser-L-Tyr-L-Phe-NH2 + NH3
-
-
-
?
L-Gln-L-Thr-Gly-L-Ile-NH2
L-pyroglutamyl-L-Thr-Gly-L-Ile-NH2 + NH3
-
-
-
?
L-glutamine tert-butyl ester
L-pyroglutamate tert-butyl ester + NH3
-
-
-
-
?
L-glutaminyl-4-methylcoumarinylamide
L-5-oxoprolyl-4-methylcoumarinylamide + NH3
-
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
L-glutamyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
L-pyroglutamyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-glutaminyl-Abeta3-40/42
5-oxoprolyl-Abeta3-40/42 + NH3
amyloid-beta peptide Abeta3-40/42
-
-
r
L-glutaminyl-Abeta3-40/42 peptide
5-oxoprolyl-Abeta3-40/42 peptide + NH3
amyloid-beta peptide Abeta3-40/42
-
-
?
L-glutaminyl-monocyte chemoattractant protein 1
5-oxoprolyl-monocyte chemoattractant protein 1 + NH3
L-glutaminyl-monocyte chemoattractant protein 3
5-oxoprolyl-monocyte chemoattractant protein 3 + NH3
i.e. MCP-3 or CCL7
-
-
?
Nepsilon-(L-gamma-glutamyl)-L-lysine
5-oxoprolyl-L-lysine + NH3
-
-
-
-
?
[Gln1]-fertilization promoting peptide
[pyroglutamyl]-fertilization promoting peptide + NH3
[Gln1]-thyrotropin releasing-hormone
[pyroglutamyl]-thyrotropin releasing-hormone + NH3
-
-
-
-
?
Gln-7-amido-4-methylcoumarin
pyroglutamic acid-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
Gln-7-amido-4-methylcoumarin
pyroglutamic acid-7-amido-4-methylcoumarin + NH3
-
-
-
?
Gln-Ala-Ala-Ser-Ala-Ala-NH2
pyroglutamic acid-Ala-Ala-Ser-Ala-Ala-NH2 + NH3
-
-
-
-
?
Gln-Ala-Ala-Ser-Ala-Ala-NH2
pyroglutamic acid-Ala-Ala-Ser-Ala-Ala-NH2 + NH3
-
-
-
-
?
Gln-tert-butyl ester
pyroglutamyl-tert-butyl ester + NH3
-
-
-
-
?
H-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
H-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
H-Gln-Asp-Glu-Leu-NH2
5-oxoprolyl-Asp-Glu-Leu-NH2 + NH3
-
-
-
?
H-Gln-Asp-Glu-Leu-NH2
5-oxoprolyl-Asp-Glu-Leu-NH2 + NH3
isoDromeQC
-
-
?
H-Gln-beta-naphthylamide
5-oxoprolyl-beta-naphthylamide + NH3
-
-
-
?
H-Gln-beta-naphthylamide
5-oxoprolyl-beta-naphthylamide + NH3
isoDromeQC
-
-
?
H-Gln-beta-naphthylamide
5-oxoprolyl-beta-naphthylamide + NH3
-
-
-
?
H-Gln-Glu-Ala-Phe-NH2
5-oxoprolyl-Glu-Ala-Phe-NH2 + NH3
-
-
-
?
H-Gln-Glu-Ala-Phe-NH2
5-oxoprolyl-Glu-Ala-Phe-NH2 + NH3
isoDromeQC
-
-
?
H-Gln-Glu-Tyr-Phe-NH2
5-oxoprolyl-Glu-Tyr-Phe-NH2 + NH3
-
-
-
?
H-Gln-Glu-Tyr-Phe-NH2
5-oxoprolyl-Glu-Tyr-Phe-NH2 + NH3
isoDromeQC
-
-
?
H-Gln-Gly-Pro-OH
5-oxoprolyl-Gly-Pro-OH + NH3
isoDromeQC
-
-
?
H-Gln-Lys-Arg-Leu-NH2
5-oxoprolyl-Lys-Arg-Leu-NH2 + NH3
-
-
-
?
H-Gln-Lys-Arg-Leu-NH2
5-oxoprolyl-Lys-Arg-Leu-NH2 + NH3
isoDromeQC
-
-
?
H-Gln-Phe-Ala-OH
5-oxoprolyl-Phe-Ala-OH + NH3
isoDromeQC
-
-
?
H-Gln-Tyr-Ala-OH
5-oxoprolyl-Tyr-Ala-OH + NH3
isoDromeQC
-
-
?
H-Gln-Val-Ala-OH
5-oxoprolyl-Val-Ala-OH + NH3
isoDromeQC
-
-
?
L-Gln(3)-amyloid-beta peptide 3-42
L-pyroglutamyl(3)-amyloid-beta peptide 3-42 + NH3
-
-
-
-
?
L-Gln(3)-amyloid-beta peptide 3-42
L-pyroglutamyl(3)-amyloid-beta peptide 3-42 + NH3
-
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
-
-
-
?
L-Gln-2-naphthylamide
5-oxoprolyl-2-naphthylamide + NH3
-
-
-
?
L-Gln-2-naphthylamide
L-pyroglutamyl-2-naphthylamide + NH3
-
reaction in cell supernatant is exclusively enzyme-catalyzed
-
-
?
L-Gln-2-naphthylamide
L-pyroglutamyl-2-naphthylamide + NH3
-
reaction in cell supernatant is exclusively enzyme-catalyzed
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-4-methylcoumarin-7-amide + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-4-methylcoumarin-7-amide + NH3
isoDromeQC
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
5-oxoprolyl-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
L-pyroglutamyl-4-methylcoumarin-7-amide + NH3
-
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
L-pyroglutamyl-4-methylcoumarin-7-amide + NH3
-
-
-
?
L-Gln-7-amido-4-methylcoumarin
L-pyroglutamyl-4-methylcoumarin-7-amide + NH3
-
-
-
?
L-Gln-L-Asp-L-Glu-L-Leu-NH2
pyroglutamyl-L-Asp-L-Glu-L-Leu-NH2 + NH3
-
-
-
-
?
L-Gln-L-Asp-L-Glu-L-Leu-NH2
pyroglutamyl-L-Asp-L-Glu-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Glu-L-Ala-L-Phe-NH2
pyroglutamyl-L-Glu-L-Ala-L-Phe-NH2 + NH3
-
-
-
-
?
L-Gln-L-Glu-L-Ala-L-Phe-NH2
pyroglutamyl-L-Glu-L-Ala-L-Phe-NH2 + NH3
-
-
-
?
L-Gln-L-Glu-L-Asp-L-Leu-NH2
5-oxoprolyl-L-Glu-L-Asp-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Glu-L-Asp-L-Leu-NH2
5-oxoprolyl-L-Glu-L-Asp-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Glu-L-Tyr-L-Phe-NH2
pyroglutamyl-L-Glu-L-Tyr-L-Phe-NH2 + NH3
-
-
-
-
?
L-Gln-L-Glu-L-Tyr-L-Phe-NH2
pyroglutamyl-L-Glu-L-Tyr-L-Phe-NH2 + NH3
-
-
-
?
L-Gln-L-Lys-L-Arg-L-Leu-NH2
5-oxoprolyl-L-Lys-L-Arg-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Lys-L-Arg-L-Leu-NH2
5-oxoprolyl-L-Lys-L-Arg-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-L-Lys-L-Arg-L-Leu-NH2
pyroglutamyl-L-Lys-L-Arg-L-Leu-NH2 + NH3
-
-
-
-
?
L-Gln-L-Lys-L-Arg-L-Leu-NH2
pyroglutamyl-L-Lys-L-Arg-L-Leu-NH2 + NH3
-
-
-
?
L-Gln-tert-butyl ester
L-pyroglutamyl-tert-butyl ester + NH3
-
-
-
?
L-Glu(3)-amyloid-beta peptide 3-42
L-pyroglutamyl(3)-amyloid-beta peptide 3-42 + H2O
-
-
-
-
?
L-Glu(3)-amyloid-beta peptide 3-42
L-pyroglutamyl(3)-amyloid-beta peptide 3-42 + H2O
-
-
-
-
?
L-Glu-2-naphthylamide
5-oxo-L-prolyl-2-naphthylamide + NH3
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
pGlu-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
pGlu-7-amido-4-methylcoumarin + NH3
-
-
-
?
L-glutaminyl-7-amido-4-methylcoumarin
pGlu-7-amido-4-methylcoumarin + NH3
-
-
-
-
?
L-glutaminyl-Abeta(3-42) peptide
5-oxoprolyl-Abeta(3-42) peptide + NH3
-
-
-
?
L-glutaminyl-Abeta(3-42) peptide
5-oxoprolyl-Abeta(3-42) peptide + NH3
a glutamate residue (E) is exposed at position 3 of Abeta(3-42) and can be converted by the enzymatic activity of glutaminyl cyclase (QC) to pE resulting in the peptide pE-Abeta(3-42). 5-Oxoproline ring formation under liberation of water. Slow conversion of N-terminal glutamate under slightly acidic pH conditions, as compared with the much faster pE formation from N-terminal glutamine
-
-
?
L-glutaminyl-amyloid beta peptide
5-oxoprolyl-amyloid beta peptide + NH3
-
-
-
-
?
L-glutaminyl-amyloid beta peptide
5-oxoprolyl-amyloid beta peptide + NH3
-
-
-
-
?
L-glutaminyl-CCL2
5-oxoprolyl-CCL2 + NH3
i.e. monocyte chemoattractant protein (MCP-1)
-
-
r
L-glutaminyl-CCL2
5-oxoprolyl-CCL2 + NH3
i.e. monocyte chemoattractant protein (MCP-1), CCL2 is a specific substrate for h-isoQC but not for h-QC
-
-
r
L-glutaminyl-monocyte chemoattractant protein 1
5-oxoprolyl-monocyte chemoattractant protein 1 + NH3
i.e. MCP-1 or CCL2
-
-
?
L-glutaminyl-monocyte chemoattractant protein 1
5-oxoprolyl-monocyte chemoattractant protein 1 + NH3
-
i.e. MCP-1 or CCL2
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
Gln-His-Pro-Glythyrotropin-releasing hormone, gonadotropin-releasing hormone and L-Gln-Tyr-Ala
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
the enzyme may participate in the posttranslational processing of hormonal precursors to pyroglutamyl peptides
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
simple intramolecular cyclization. The mechanism consists of the following main steps: 1. intramolecular nucleophilic attack on the gamma-C=O carbon by the nitrogen of the alpha-amino group, 2. transfer of a proton from the alpha-amino group to the nitrogen of the amide group, facilitated by an acidic group of the enzyme, 3. expulsion of the ammonia-leaving group promoted by this or another acidic enzyme group
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
the N-terminal formation of 5-oxoproline is a common post-translational event during biosynthesis of a number of peptides
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
Gln-His-Pro-Glythyrotropin-releasing hormone, gonadotropin-releasing hormone and L-Gln-Tyr-Ala
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
thyrotropin-releasing hormone
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
[Gln1]-fertilization promoting peptide
[pyroglutamyl]-fertilization promoting peptide + NH3
-
-
-
-
?
[Gln1]-fertilization promoting peptide
[pyroglutamyl]-fertilization promoting peptide + NH3
-
-
-
-
?
[Gln1]-gonadotropin releasing-hormone
[pyroglutamyl]-gonadotropin releasing-hormone + NH3
-
-
-
-
?
[Gln1]-gonadotropin releasing-hormone
[pyroglutamyl]-gonadotropin releasing-hormone + NH3
-
-
-
-
?
additional information
?
-
-
highest specificities are observed with substrates possessing large hydrophobic residues adjacent to the N-terminal glutamine and for fluorogenic dipeptide surrogates. Enzyme also catalyzes the conversion of N-terminal glutamic acid residues to pyroglutamic acid, but with about 100000fold lower specificity
-
-
?
additional information
?
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
-
no substrates are D-Gln-Tyr-Ala and Lys-Arg-Gln-His-Pro-Gly-Lys-Arg, i.e. thyrotropin releasing hormone precursor
-
-
?
additional information
?
-
-
Cys residues do not participate to the catalytic events
-
-
?
additional information
?
-
-
the second amino acid residue in N-terminal glutaminyl peptides significantly accelerates activity while the third residue provides no further rate enhancement. Substrate binding is the main specificity-determining step
-
-
?
additional information
?
-
-
the enzyme may play a key role in posttranslational modification
-
-
?
additional information
?
-
-
the enzyme may play a key role in posttranslational modification
-
-
?
additional information
?
-
-
enzyme is important during cellular maturation of L-pyroglutamyl-containing peptides
-
-
?
additional information
?
-
-
catalyzes the formation of amyloid-beta3(pE)-40/42 after amyloidogenic processing of amyloid precursor protein
-
-
?
additional information
?
-
orexin A, gastrin, gonadotropin, TRH, MCP-1 to 4, FPP, fibronectin, and neurotensin are substrates of the enzyme
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview. CCL2 is a specific substrate for h-isoQC but not for h-QC
-
-
-
additional information
?
-
cyclization reaction of glutamate and glutamine residues, overview. CCL2 is a specific substrate for h-isoQC but not for h-QC
-
-
-
additional information
?
-
-
enzyme is important during cellular maturation of L-pyroglutamyl-containing peptides
-
-
?
additional information
?
-
the enzyme shows no activity towards L-Gln-Gly
-
-
?
additional information
?
-
-
the enzyme does not act on L-2-amino-3-(3-n-butylureido)-propionic acid, L-glutamine, L-gamma-glutamyl-L-lysine, L-gamma-glutamyl-L-methionine, or L-gamma-glutamyl-L-glutamine
-
-
?
additional information
?
-
-
no substrates are D-Gln-Tyr-Ala and Lys-Arg-Gln-His-Pro-Gly-Lys-Arg, i.e. thyrotropin releasing hormone precursor
-
-
?
additional information
?
-
-
highest specificities are observed with substrates possessing large hydrophobic residues adjacent to the N-terminal glutamine and for fluorogenic dipeptide surrogates. Enzyme also catalyzes the conversion of N-terminal glutamic acid residues to pyroglutamic acid, but with about 100000fold lower specificity
-
-
?
additional information
?
-
highest specificities are observed with substrates possessing large hydrophobic residues adjacent to the N-terminal glutamine and for fluorogenic dipeptide surrogates. Enzyme also catalyzes the conversion of N-terminal glutamic acid residues to pyroglutamic acid, but with about 100000fold lower specificity
-
-
?
additional information
?
-
the enzyme shows no activity towards QAAR
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
L-glutaminyl-Abeta(3-42) peptide
5-oxoprolyl-Abeta(3-42) peptide + NH3
a glutamate residue (E) is exposed at position 3 of Abeta(3-42) and can be converted by the enzymatic activity of glutaminyl cyclase (QC) to pE resulting in the peptide pE-Abeta(3-42). 5-Oxoproline ring formation under liberation of water. Slow conversion of N-terminal glutamate under slightly acidic pH conditions, as compared with the much faster pE formation from N-terminal glutamine
-
-
?
L-glutaminyl-Abeta3-40/42
5-oxoprolyl-Abeta3-40/42 + NH3
amyloid-beta peptide Abeta3-40/42
-
-
r
L-glutaminyl-Abeta3-40/42 peptide
5-oxoprolyl-Abeta3-40/42 peptide + NH3
amyloid-beta peptide Abeta3-40/42
-
-
?
L-glutaminyl-CCL2
5-oxoprolyl-CCL2 + NH3
i.e. monocyte chemoattractant protein (MCP-1)
-
-
r
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
the enzyme may participate in the posttranslational processing of hormonal precursors to pyroglutamyl peptides
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
the N-terminal formation of 5-oxoproline is a common post-translational event during biosynthesis of a number of peptides
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
L-glutaminyl-peptide
5-oxoprolyl-peptide + NH3
-
involved in posttranslational modification of the N-terminal glutamine of peptide hormones or neurotransmitters, such as thyrotropin releasing hormone, luteinizing hormone releasing hormone, gastrin, heavy chain of gamma-globulin
-
-
?
additional information
?
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
-
enzyme is involved in N-terminal pyroglutamate formation of snake venom toxins
-
-
?
additional information
?
-
-
the enzyme may play a key role in posttranslational modification
-
-
?
additional information
?
-
-
the enzyme may play a key role in posttranslational modification
-
-
?
additional information
?
-
-
enzyme is important during cellular maturation of L-pyroglutamyl-containing peptides
-
-
?
additional information
?
-
orexin A, gastrin, gonadotropin, TRH, MCP-1 to 4, FPP, fibronectin, and neurotensin are substrates of the enzyme
-
-
-
additional information
?
-
-
enzyme is important during cellular maturation of L-pyroglutamyl-containing peptides
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Co2+
enzyme inactivated by 1,10-phenanthroline or dipicolinic acid can be restored partially by Co2+ or Mn2+
Mn2+
enzyme inactivated by 1,10-phenanthroline or dipicolinic acid can be restored partially by Co2+ or Mn2+
Zinc
Zn2+
additional information
Zinc
stoichiometric amounts of zinc bound to protein. Depletion of zinc has no significant effect on protein structure, metal has a catalytic role
Zn2+
enzyme inactivated by 1,10-phenanthroline or dipicolinic acid can be fully restored by addition of Zn2+ in the presence of equimolar concentrations of EDTA
Zn2+
the active site is coordinated to three conserved residues and one water molecule, which is replaced by an imidazole nitrogen upon binding of inhibitor
Zn2+
involved in catalysis, the Zn2+ ion located at the active site of QC polarizes the gamma-amide group of the substrate Gln residue and stabilizes the oxyanion formed by the nucleophilic attack of the alpha-nitrogen on the scissile gamma-carbonyl carbon
additional information
-
substrate specificity for substrates with uncharged backbone and for Gln-Ala and Gln-Glu, does not change significantly by salt addition. With the positively charged substrates Gln-Arg-Gly-Ile-NH2 and Gln-Lys-Arg-Leu-NH2 addition of salt reveals a positive effect on catalysis
additional information
human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. Glutaminyl cyclase does not appear to require zinc for enzymatic activity
additional information
-
human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. Glutaminyl cyclase does not appear to require zinc for enzymatic activity
additional information
-
substrate specificity for substrates with uncharged backbone does not change significantly by salt addition. For substrates such as Gln-Ala and Gln-Glu, addition of KCl decreases specificity. With the positively charged substrates Gln-Arg-Gly-Ile-NH2 and Gln-Lys-Arg-Leu-NH2 addition of salt reveals a positive effect on catalysis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(3,4-dichlorophenyl)-2-cyano-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-(4-(trifluoromethyl)phenyl)guanidine
-
(3-(4-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)guanidine
-
(E)-N1-(5-methyl-1H-imidazol-1-yl)-2-nitro-N'1-[4-(trifluoromethyl)phenyl]ethene-1,1-diamine
-
1-(3,4-dimethoxyphenyl)-3-(2-[1-(1H-imidazol-1-yl)cyclopropyl]ethyl)thiourea
-
-
1-(3,4-dimethoxyphenyl)-3-(3-(4-methyl-1H-imidazol-1-yl)propyl)thiourea
-
1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
1-(3,4-dimethoxyphenyl)-N-(1H-imidazol-1-yl)cyclopropane-1-carbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(3-(4-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(4-methyl-1H-imidazol-1-yl)cyclopropane-1-carbothioamide
-
1-(3,4-dimethoxyphenyl)-N-(5-methyl-1H-imidazol-1-yl)cyclopropane-1-carbothioamide
-
1-(3,4-dimethoxyphenyl)-N-[3-(1H-imidazol-1-yl)propyl]cyclopropane-1-carbothioamide
-
2,3-dihydro-3-(3-(4-methyl-1H-imidazol-1-yl)propyl)-2-thioxoquinazolin-4(1H)-one
-
2,3-dihydro-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-thioxoquinazolin-4(1H)-one
-
2,3-dihydro-6-methyl-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-2-thioxothieno[2,3-d]pyrimidin-4(1H)-one
-
2-(2,3-dimethoxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
87.7% inhibition at 0.1 mM
2-(2,3-dimethoxyphenyl)-7-hydroxy-4H-chromen-4-one
54.3% inhibition at 0.1 mM
2-(2,4-dimethoxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
71.7% inhibition at 0.1 mM
2-(2-fluorophenyl)-5,7-dihydroxy-4H-chromen-4-one
84.2% inhibition at 0.1 mM
2-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromen-4-one
68.3% inhibition at 0.1 mM
2-(4-(dimethylamino)phenyl)-7-hydroxy-4H-chromen-4-one
90.3% inhibition at 0.1 mM
2-(4-ethoxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
91.5% inhibition at 0.1 mM
2-(4-ethylphenyl)-5,7-dihydroxy-4H-chromen-4-one
85.2% inhibition at 0.1 mM
2-cyano(3,4,5-trimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine
-
2-cyano(3-(5-methyl-1H-imidazol-1-yl)propyl)-3-(3,4-dimethylphenyl)guanidine
-
2-cyano-1-[3-(5-methyl-1H-imidazol-1-yl)propyl]-4-phenylbenzene-1-guanidine
-
3-(3-(1H-imidazol-1-yl)propyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one
-
3-(3-(1H-imidazol-1-yl)propyl)-2,3-dihydro-7-methyl-2-thioxothieno[3,2-d]pyrimidin-4(1H)-one
-
3-(5-methyl-1H-imidazol-1-yl)-6-phenyl-2-sulfanylidene-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one
-
3-fluoro-3',4'-dimethoxy-N-[3-(4-methyl-1H-imidazol-1-yl)propyl][1,1'-biphenyl]-2-amine
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-1,2,3,5,6,7-hexahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8,9,10-octahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-sulfanylidene-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-sulfanylidene-2,3-dihydroquinazolin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8,9,10-octahydrocycloocta[4,5]-thieno[2,3-d]pyrimidin-4(1H)-one
-
3-[3-(5-methyl-1H-imidazol-1-yl)propyl]-2-thioxo-2,3,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-4(1H)-one
-
4'-fluoro-N-[3-(4-methyl-1H-imidazol-1-yl)propyl][1,1'-biphenyl]-2-amine
-
4-[2-[4-([1-[(3-aminophenyl)methyl]-1H-imidazol-2-yl]methyl)-1H-imidazol-1-yl]ethoxy]benzaldehyde
-
5,6-dimethoxy-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1Hbenzo[d]imidazol-2-amine
-
5,6-dimethoxy-N-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1,3-benzothiazol-2-amine
-
5,6-dimethoxy-N-[3-(5-methyl-1H-imidazol-1-yl)propyl]-1H-benzimidazol-2-amine
-
5,7-dihydroxy-2-(3-methylthiophen-2-yl)-4H-chromen-4-one
91.6% inhibition at 0.1 mM
5,7-dihydroxy-2-(5-methylthiophen-2-yl)-4H-chromen-4-one
92.4% inhibition at 0.1 mM
5,7-dihydroxy-2-(thiophen-2-yl)-4H-chromen-4-one
92.6% inhibition at 0.1 mM
5-(5-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
-
5-(5-[[(pyridin-4-yl)methyl]sulfanyl]-1,3,4-oxadiazol-2-yl)-1H-benzimidazole
-
6-benzyl-2,3-dihydro-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-thioxothieno[2,3-d]pyrimidin-4(1H)-one
-
7-hydroxy-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4-one
70.8% inhibition at 0.1 mM
7-hydroxy-2-(2-methoxyphenyl)-4H-chromen-4-one
54.5% inhibition at 0.1 mM
7-hydroxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one
68.7% inhibition at 0.1 mM
7-hydroxy-2-(4-(methylthio)phenyl)-4H-chromen-4-one
75.8% inhibition at 0.1 mM
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
71.8% inhibition at 0.1 mM
7-hydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
75.2% inhibition at 0.1 mM
7-hydroxy-2-(5-methylfuran-2-yl)-4H-chromen-4-one
78.9% inhibition at 0.1 mM
diethyl dicarbonate
-
rapid inactivation by modification of three essential His residues, at neutral pH, partial reactivation with hydroxylamine
L-glutamine-4-nitroanilide
substrate inhibition; substrate inhibition, isoDromeQC
methyl N-[(2S)-1-hydroxy-2-[[3-(5-methyl-1H-imidazol-1-yl)propyl]amino]-3-phenylpropyl]-L-alaninate
-
N''-cyano-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]guanidine
-
N''-cyano-N-(5-methyl-1H-imidazol-1-yl)-N'-(3,4,5-trimethoxyphenyl)guanidine
-
N''-cyano-N-methyl-N'-[3-(4-methyl-1H-imidazol-1-yl)propyl]guanidine
-
N''-cyano-N-methyl-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]guanidine
-
N-((E)-4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-((E)-4-(3-oxo-3-(piperazin-1-yl)prop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-((E)-4-(3-oxo-3-(piperidin-4-ylamino)prop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-3,4-dimethoxy-benzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-(trifluoromethyl)-benzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-chlorobenzenamine
-
N-(1-(3-(1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-methoxybenzenamine
-
N-(1-(3-(4-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-2,3-dihydrobenzo[b][1,4]-dioxin-6-amine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-(trifluoromethyl)benzenamine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)-4-chloro-benzenamine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)cyclohexanamine
-
N-(1-(3-(5-methyl-1H-imidazol-1-yl)propylamino)-2-nitrovinyl)naphthalen-1-amine
-
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-(3,4-dimethoxyphenyl)-4-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,3-thiazol-2-amine
-
N-(3,4-dimethoxyphenyl)-5-[2-(5-methyl-1H-imidazol-1-yl)ethyl]-1,3,4-oxadiazol-2-amine
-
N-(3,4-dimethoxyphenyl)-N'-[3-(1H-imidazol-1-yl)-2-methylpropyl]thiourea
-
N-(3-(2-(2-aminopyridin-4-yl)ethoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(2-aminoethoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(3-(2-aminopyridin-4-yl)propoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(3-aminopropoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(4-(2-aminopyridin-4-yl)butoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(4-(dimethylamino)butoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-(4-aminobutoxy)-4-methoxyphenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(3-methoxy-4-[[4-(piperidin-4-yl)phenyl]methoxy]phenyl)-N'-[3-(5-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-(4-((1-(2-aminoethyl)piperidin-4-yl)carbamoyl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-(((2-aminopyridin-4-yl)methyl)amino)-2-oxoethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-((1-(2-aminoethyl)piperidin-4-yl)amino)-2-oxoethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-oxo-2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(2-oxo-2-(piperidin-4-ylamino)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-(4-(2-aminopyridin-4-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-chlorophenyl)-N'-[2-(1H-imidazol-1-yl)propyl]-2-thioxoimidazolidin-4-one
-
N-(4-methoxy-3-(2-(1-methylpiperidin-4-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(2-(piperazin-1-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(2-(piperidin-4-yl)ethoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(3-(methylamino)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(3-(piperazin-1-yl)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(3-(piperidin-4-yl)propoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(methylamino)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(piperazin-1-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(piperidin-4-yl)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-methoxy-3-(4-(pyrimidin-2-ylamino)butoxy)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-(4-[(1E)-3-[4-(2-aminoethyl)piperazin-1-yl]-3-oxoprop-1-en-1-yl]phenyl)-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-(E)-(4-(3-(4-(2-aminoethyl)piperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)-N'-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
-
N-[3-(4-aminobutoxy)-4-methoxyphenyl]-N'-[3-(2-methyl-1H-imidazol-1-yl)propyl]thiourea
-
N-[3-methoxy-4-[(piperidin-4-yl)methoxy]phenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-(2-aminoethoxy)-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-(3-aminopropoxy)-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-(4-aminobutoxy)-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N-[4-[3-(2-aminopyridin-4-yl)propoxy]-3-methoxyphenyl]-N'-(5-methyl-1H-imidazol-1-yl)thiourea
-
N2-[(2S)-1-hydroxy-2-[[3-(5-methyl-1H-imidazol-1-yl)propyl]amino]-3-phenylpropyl]-L-alaninamide
-
PQ529
can efficiently inhibit the activity of both glutaminyl cyclase isozymes QC and isoQC. Treatment with PQ529 for 48 h significantly blocks the binding of CC2C6 to the cell surface in a dosage-dependent manner in wild-type, but not in isoQC-deficient cells
SEN-177
the triazole based inhibitor, SEN177 coordinates with the catalytically important Zn2+ ion of sQC and has made several hydrophobic interactions with active site residues such as W207, F325, and W329
1,10-phenanthroline
inactivated enzyme can be fully restored by addition of Zn2+ in the presence of equimolar concentrations of EDTA, little reactivation by Co2+ and Mn2+
1,2-di-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glycopyranosyl)-glycerol
-
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
i.e. P150/03, complete inhibition at 0.01 mM
1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea
-
i.e. P150/03, complete inhibition at 0.01 mM
1-O-linolyl-2-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-O-linolyl-2-O-palmitoyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-O-palmitoyl-2-O-linolenyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
1-O-palmitoyl-2-O-linolenyl-3-O-(6'-deoxy-6'-sulfo-D-glucopyranosyl)-glycerol
-
dipicolinic acid
inactivated enzyme can be fully restored by addition of Zn2+ in the presence of equimolar concentrations of EDTA, little reactivation by Co2+ and Mn2+
EFRH-NH2
-
competitive inhibitor with L-glutaminyl-7-amido-4-methylcumarin as substrate
EFRH-NH2
-
competitive inhibitor with L-glutaminyl-7-amido-4-methylcumarin as substrate
EFRHHDSGYE-NH2
-
competitive inhibitor with L-glutaminyl-7-amido-4-methylcumarin as substrate
EFRHHDSGYE-NH2
-
competitive inhibitor with L-glutaminyl-7-amido-4-methylcumarin as substrate